BMS Reports Results of Opdivo (nivolumab) in P-III CheckMate -274 Study for Patients with High-Risk Muscle-Invasive Urothelial Carcinoma

 BMS Reports Results of Opdivo (nivolumab) in P-III CheckMate -274 Study for Patients with High-Risk Muscle-Invasive Urothelial Carcinoma

BMS Reports Results of Opdivo (nivolumab) in P-III CheckMate -274 Study for Patients with High-Risk Muscle-Invasive Urothelial Carcinoma

Shots:

  • The P-III CheckMate -274 study involves assessing of Opdivo vs PBO in 709 patients in a ratio (1:1) with muscle-invasive urothelial cancer at a high risk of recurrence after radical surgery for up to 1yr.
  • The study met its 1EPs of DFS in both all randomized patients and in patients whose tumor cells express PD-L1 ≥1% and showed a reduction in risk of relapse in the adjuvant settings, safety profile is consistent with previous studies in solid tumors
  • The company will continue the study as planned to allow for future analyses of 2EPs, including OS and disease-specific survival.  Opdivo is a PD-1 immune check inhibitor harnessing the body’s own immune system to restore anti-tumor immune response

Click here ­to­ read full press release/ article | Ref: BMS | Image: The Social Medwork

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post